Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
Disclosed herein are methods of treating conditions, which may be associated with elevated levels of plasma cells and/or B-cells, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
1. A method of treating multiple myeloma in a subject comprising administering to the subject in need thereof a therapeutically effective amount of dexpramipexole or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole is from about 1 mg to about 1,000 mg per day.
3. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole is from about 50 mg to about 600 mg per day.
4. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole is from about 150 mg to about 300 mg per day.
5. The method of claim 1 , wherein administering is selected from a group consisting of administering a fraction of the therapeutically effective amount two or more times per day, administering an amount equal to about half of the therapeutically effective amount twice per day, and administering the therapeutically effective amount every 12 hours.
6. The method of claim 1 , wherein administering comprises administering about 150 mg two times per day.
7. The method of claim 1 , further comprising an induction step, wherein said induction step is selected from a group consisting of administering a therapeutic agent selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent, a phenolic antioxidant, an anti-proliferative drug, an anti IL-5 monoclonal antibody, an IL-5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an anti IL-4 monoclonal antibody, an anti IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a TNF-α inhibitor, a fusion protein, an anti-inflammatory drug, and a combination thereof.
8. The method of claim 7 , wherein the tyrosine kinase inhibitor is imatinib.
9. The method of claim 7 , wherein the anti IL-5 monoclonal antibody is selected from the group consisting of mepolizumab and reslizumab.
10. The method of claim 7 , wherein the IL-5 receptor monoclonal antibody is benralizumab.
11. The method of claim 7 , wherein the anti IL-13 monoclonal antibody is lebrikizumab.
12. The method of claim 7 , wherein the anti IL-4 receptor monoclonal antibody is dupilumab.
13. The method of claim 7 , wherein the anti IgE monoclonal antibody is omalizumab.
14. The method of claim 7 , wherein the TNF-α inhibitor is selected from the group consisting of infliximab, adalimumab, certolizumab pegol, and golimumab.
15. The method of claim 7 , wherein the fusion protein is etanercept.
16. The method of claim 1 , wherein administering comprises administering about 75 mg two times per day.
17. The method of claim 1 , wherein administering comprises administering about 300 mg two times per day.
18. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole is administered as an initial dosing regimen and then as a maintenance dosing regimen.
19. The method of claim 18 , wherein the therapeutically effective amount of the initial dosing regimen is from about 50 mg to about 1,500 mg per day.
20. The method of claim 18 , wherein the therapeutically effective amount of the initial dosing regimen is from about 150 mg to about 300 mg per day.
21. The method of claim 18 , wherein the therapeutically effective amount of the initial dosing regimen is from about 300 mg to about 500 mg per day.
22. The method of claim 18 , wherein the therapeutically effective amount of the initial dosing regimen is from about 300 mg to about 600 mg per day.
23. The method of claim 18 , wherein the therapeutically effective amount of the maintenance dosing regimen is from about 50 mg to about 1,500 mg per day.
24. The method of claim 18 , wherein the therapeutically effective amount of the maintenance dosing regimen is from about 150 mg to about 300 mg per day.
25. The method of claim 18 , wherein the therapeutically effective amount of the maintenance dosing regimen is from about 300 mg to about 500 mg per day.
26. The method of claim 18 , wherein the therapeutically effective amount of the maintenance dosing regimen is from about 300 mg to about 600 mg per day.
27. The method of claim 1 , wherein the therapeutically effective amount is administered orally.
28. The method of claim 1 , wherein the therapeutically effective amount is administered topically.